Stephens Investment Management Group LLC Has $53.89 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Stephens Investment Management Group LLC cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 747,535 shares of the medical equipment provider's stock after selling 71,293 shares during the period. Stephens Investment Management Group LLC owned approximately 0.33% of Hologic worth $53,890,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Czech National Bank raised its position in Hologic by 6.4% during the third quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider's stock valued at $3,854,000 after purchasing an additional 2,843 shares during the period. Marcum Wealth LLC purchased a new stake in Hologic during the third quarter valued at approximately $202,000. Wedmont Private Capital raised its position in Hologic by 3.7% during the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock valued at $361,000 after purchasing an additional 162 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its position in Hologic by 257.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,826 shares of the medical equipment provider's stock valued at $230,000 after purchasing an additional 2,036 shares during the period. Finally, First Affirmative Financial Network purchased a new stake in Hologic during the third quarter valued at approximately $242,000. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Jefferies Financial Group began coverage on Hologic in a research note on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price for the company. UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating for the company. Finally, Raymond James restated an "outperform" rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $85.77.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Trading Down 1.5 %

NASDAQ HOLX traded down $0.94 on Wednesday, reaching $63.53. The stock had a trading volume of 2,008,332 shares, compared to its average volume of 2,567,055. The firm has a market capitalization of $14.34 billion, a price-to-earnings ratio of 20.04, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $63.45 and a 12-month high of $84.67. The stock has a fifty day moving average price of $71.53 and a two-hundred day moving average price of $77.47.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.